Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

anti-inflammatory

- PMLiVE

AbbVie’s Rinvoq recommended by NICE for Crohn’s disease

It is estimated that over 155,000 adults are living with the condition in the UK

- PMLiVE

Janssen and AbbVie’s Imbruvica combination recommended by NICE for leukaemia

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

- PMLiVE

AbbVie’s Rinvoq approved by EC for Crohn’s disease

The therapy is now the first oral JAK inhibitor authorised to treat this patient population

- PMLiVE

AbbVie’s Parkinson’s disease therapy application rejected by FDA

The regulator has requested more information on the pump used to administer ABBV-95

- PMLiVE

AbbVie’s Rinvoq approved by MHRA for Crohn’s disease

Over 155,000 adults in the UK are estimated to have the disease, with 40% of them having moderate or severe symptoms

- PMLiVE

AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement

Both companies will now come under the scheme imposed by the government through law

- PMLiVE

AbbVie and Anima Biotech collaborate on mRNA biology modulators

The biotech could receive up to $540m in milestone payments for three targets

- PMLiVE

AbbVie and Immunome agree on multi-year oncology collaboration

The companies will identify up to ten antibody-target pairs using Immunome's discovery engine

- PMLiVE

bluebird bio sells second FDA priority review voucher for $95m

The company sold its first voucher to Dutch biotech Argenx for $102m

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies

The company can now resume the enrolment and treatment of patients aged two to 17 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links